tradingkey.logo

Femasys Inc

FEMY
查看詳細走勢圖
0.861USD
+0.064+7.97%
收盤 12/19, 16:00美東報價延遲15分鐘
40.73M總市值
虧損本益比TTM

Femasys Inc

0.861
+0.064+7.97%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

+7.97%

5天

+0.51%

1月

+7.60%

6月

+1.31%

今年開始到現在

-21.72%

1年

-21.00%

查看詳細走勢圖

TradingKey Femasys Inc股票評分

單位: USD 更新時間: 2025-12-19

操作建議

Femasys Inc當前公司基本面數據相對健康,增長潛力較大。當前估值合理,在醫療設備與耗材行業排名132/208位。機構持股佔比非常高,近一個月多位分析師給出公司評級為買入。最高目標價5.17。中期看,股價處於上升通道。近一個月,市場表現較差,但技術面評分較高。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Femasys Inc評分

相關信息

行業排名
132 / 208
全市場排名
311 / 4582
所屬行業
醫療設備與耗材

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

分析師目標

基於 3 分析師
買入
評級
5.167
目標均價
+532.01%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

Femasys Inc亮點

亮點風險
Femasys Inc. is a biomedical company. The Company is focused on addressing the unmet needs of women worldwide with a broad portfolio of in-office, accessible, and therapeutic and diagnostic solutions. The Company has two lead product candidates: FemBloc and FemaSeed. FemBloc is a permanent birth control solution in development. Its permanent birth control solution in development includes its FemBloc system, which features dual intrauterine directional delivery targeting both fallopian tubes with a degradable blended biopolymer. FemaSeed is an artificial insemination infertility treatment. Its artificial insemination solution in development includes its FemaSeed product candidate for artificial insemination, which features single intrauterine directional delivery. It also developed FemCerv, which is an endocervical tissue sampler for cervical cancer diagnosis; FemVue, which is a companion diagnostic for fallopian tube assessment; FemCath, which is an intrauterine catheter, and FemChec.
業績高增長
公司營業收入穩步增長,連續3年增長35.06%
業績增長期
公司處於發展階段,最新年度總收入1.63M美元
利潤高增長
公司淨利潤處於行業前列,最新年度總收入1.63M美元
估值合理
公司最新PE估值-1.25,處於3年歷史合理位
先鋒集團持倉
明星投資者先鋒集團持倉,最新持倉951.87K股
活躍度增加
近期活躍度增加,過去20天平均換手率0.15

Femasys Inc新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Femasys Inc簡介

Femasys Inc. is a biomedical company. The Company is focused on addressing the unmet needs of women worldwide with a broad portfolio of in-office, accessible, and therapeutic and diagnostic solutions. The Company has two lead product candidates: FemBloc and FemaSeed. FemBloc is a permanent birth control solution in development. Its permanent birth control solution in development includes its FemBloc system, which features dual intrauterine directional delivery targeting both fallopian tubes with a degradable blended biopolymer. FemaSeed is an artificial insemination infertility treatment. Its artificial insemination solution in development includes its FemaSeed product candidate for artificial insemination, which features single intrauterine directional delivery. It also developed FemCerv, which is an endocervical tissue sampler for cervical cancer diagnosis; FemVue, which is a companion diagnostic for fallopian tube assessment; FemCath, which is an intrauterine catheter, and FemChec.
公司代碼FEMY
公司Femasys Inc
CEOLee-Sepsick (Kathy)
網址https://www.femasys.com/

常見問題

Femasys Inc(FEMY)的當前股價是多少?

Femasys Inc(FEMY)的當前股價是 0.861。

Femasys Inc 的股票代碼是什麼?

Femasys Inc的股票代碼是FEMY。

Femasys Inc股票的52週最高點是多少?

Femasys Inc股票的52週最高點是1.800。

Femasys Inc股票的52週最低點是多少?

Femasys Inc股票的52週最低點是0.307。

Femasys Inc的市值是多少?

Femasys Inc的市值是40.73M。

Femasys Inc的淨利潤是多少?

Femasys Inc的淨利潤為-18.82M。

現在Femasys Inc(FEMY)的股票是買入、持有還是賣出?

根據分析師評級,Femasys Inc(FEMY)的總體評級為買入,目標價格為5.167。

Femasys Inc(FEMY)股票的每股收益(EPS TTM)是多少

Femasys Inc(FEMY)股票的每股收益(EPS TTM)是-0.687。
KeyAI